Home / Innere Medizin / Onkologie / A sliver of hope for head and neck cancer

A sliver of hope for head and neck cancer

A small study, presented at ESMO Congress 2018 suggests that the orally administered fibroblast growth factor receptor (FGFR) inhibitor rogaratinib could be beneficial for a subset of patients with head and neck cancer.
Dr. Markus Jörger, Kantonsspital St. Gallen, presenting the collective outcome of two combined phase I trials.

So profitieren Sie von medonline.ch

  • eLearnings, Literaturstudien
  • Aktuelle Fachartikel, State-of-the-Art-Beiträge, Kongressberichte, Experteninterviews
  • Produktfortbildung

 

Melden Sie sich jetzt an & und bleiben Sie top-informiert!

LOGIN

Login

Passwort vergessen?